research Adverse events in patients treated with Jak‐inhibitors for alopecia areata: A systematic review
JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.
Search
for
Sort by
Research
570-600 / 1000+ results 
research Az alopecia areata kezelésében alkalmazott baricitinib hatásosságának és biztonságosságának retrospektív vizsgálata = Efficacy and safety of baricitinib treatment in alopecia areata:a retrospective analysis
Baricitinib is effective and safe for treating severe alopecia areata.
research rwSALT: a regrowth-weighted SALT score providing direct pixel-level measurement rather than visual estimation
rwSALT provides precise hair regrowth measurement from scalp photos.
research Topical tofacitinib for patients with lichen planopilaris and/or frontal fibrosing alopecia
Topical tofacitinib cream may help treat certain hair loss conditions with fewer risks.
research SYSTEMATIC REVIEW OF PHARMACOTHERAPY STRATEGIES IN THE MANAGEMENT OF HIDRADENITIS SUPPURATIVA
Biologic agents are effective for severe hidradenitis suppurativa when other treatments fail.
research [Methotrexate to treat SAPHO syndrome with keloidal scars].
Methotrexate effectively managed SAPHO syndrome symptoms when other treatments failed.
research 43647 Treatment of Refractory Folliculitis Decalvans with the Topical JAK Inhibitor Tofacitinib
Topical tofacitinib helped a man with severe scalp condition after other treatments failed.
research 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)
Oral JAK inhibitors improved alopecia areata by modulating immune responses and boosting hair growth.
research Sickle Cell Disease Complications and BMI Percentiles of Pediatric Patients
Sickle cell disease affects BMI and pain frequency, with HbSS patients having more pain and unhealthy BMI.
research Comparison of quality of life in patients with androgenetic alopecia and alopecia areata
Both androgenetic alopecia and alopecia areata negatively impact quality of life, with no significant difference between them.
research How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach
Baricitinib 4 mg should be used for at least 1 year to see significant hair regrowth in severe alopecia areata.
research Tofacitinib Loaded Squalenyl Nanoparticles for Targeted Follicular Delivery in Inflammatory Skin Diseases
Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.
research Therapeutic Response of Alopecia Areata‐Associated Nail Changes to Baricitinib
Baricitinib may effectively treat nail changes in alopecia areata.
research 706 Predictive modeling of patient response to JAK/STAT inhibitors and dynamic patient-matching
Machine learning can predict how well patients with alopecia areata will respond to certain treatments.
research Risk Factors for the Development of and Outcomes After Diagnosis of Autoimmune Alopecia Areata in Patients with Inflammatory Bowel Diseases
research Quantitative assessment of female pattern hair loss
Computer-aided imaging system helps measure balding area in female pattern hair loss.
research Evaluation of the serum C‐reactive protein–albumin ratio and its relationship with disease severity IN alopecia areata: A prospective case–control study
CAR is a useful marker for assessing alopecia areata severity.
research Refractory alopecia in lupus treated with tofacitinib — a case-based review
Tofacitinib helped regrow hair in a lupus patient with alopecia.
research Treatment of persistent alopecia areata with sulfasalazine
Sulfasalazine may help treat persistent alopecia areata.
research Distribution of SALT Scores with Ritlecitinib Treatment up to 24 months from the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata
Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.
research Development and testing of a decision board to help clinicians present treatment options to lupus nephritis patients in Brazil
The decision board effectively helps lupus nephritis patients in Brazil choose treatments by clearly presenting options and side effects.
research Generalized pruritus in primary sclerosing cholangitis: implications of histamine release by lysophosphatidic acid
A certain medication improved severe itching in a boy with liver and bowel disease by reducing histamine levels, suggesting a new treatment target.
research Prevalence of skin lesions in a sample of Brazilian patients with inflammatory bowel disease
Brazilian patients with inflammatory bowel disease have a high rate of skin problems compared to healthy people.
research Forsythiaside A ameliorates sepsis-induced acute kidney injury via anti-inflammation and antiapoptotic effects by regulating endoplasmic reticulum stress
Forsythiaside A reduces kidney damage from sepsis by lowering inflammation and cell death.
research Development and Validation of a Dermoscopic Severity Score for Female Pattern Hair Loss
A reliable severity score for female pattern hair loss was developed and validated.
research Cross sectional quality of life assessment in patients with androgenetic alopecia
Hair loss lowers quality of life, causing embarrassment, frustration, and sexual rejection.
research Increased serum interleukin-17A levels correlate with disease severity and poor prognostic factors in patients with alopecia areata
Higher IL-17A levels indicate more severe alopecia areata.
research Clinical Efficacy and Safety of Baricitinib in Patients With Alopecia Areata in Korea
Baricitinib is effective and safe for treating alopecia areata in Korea.
research A pan-European register-based observational study of abrocitinib and conventional systemic therapies in moderate and severe atopic dermatitis: the DREAM TO TREAT AD study protocol
Abrocitinib is being evaluated for safety and effectiveness in treating moderate to severe atopic dermatitis.
research A Randomised-Controlled Study Demonstrates That Diet Can Contribute to the Clinical Management of Feline Atopic Skin Syndrome (FASS)
A special diet can help manage Feline Atopic Skin Syndrome and reduce medication needs in cats.